Objective: To evaluate the efficacy and safety of topiramate as adjunctive
therapy for Lennox-Gastaut syndrome in a multicenter, double-blind, placebo
-controlled trial. Background: Conventional antiepileptic drugs are frequen
tly ineffective against multiple-seizure types of Lennox-Gastaut syndrome.
Methods: Ninety-eight patients >1 year to <30 years of age, with slow spike
-and-wave patterns on EEG, seizure types including drop attacks, and either
a history of or active atypical absence seizures, were assigned to an 11-w
eek, double-blind treatment phase with either topiramate or placebo. Topira
mate was titrated to target doses pf;approximately 6 mg/kg/d. Results: For
drop attacks, the most severe seizures associated with this syndrome,the me
dian percentage reduction from baseline in average monthly seizure rate was
14.8% for the topiramate group and -5.1% tan increase) for the placebo gro
up (p = 0.041). Topiramate-treated patients demonstrated greater improvemen
t in seizure severity than did placebo-treated patients based on parental g
lobal evaluations (p = 0.037). The percentage of patients with a greater th
an or equal to 50% reduction from baseline in major seizures (drop attacks
and tonic-clonic seizures) was greater in the topiramate group (15/46 or 33
%) than in the control group (4/50 or 8%; p = 0.002). The most common adver
se events in both groups were GNS related; there were no discontinuations f
rom topiramate therapy due to adverse events. Conclusions: Topiramate adjun
ctive therapy was effective in reducing the number of drop attacks and majo
r motor seizures and in improving seizure severity as determined by parenta
l global evaluation.